People's Custom Rx and Clinical Care, LLC, Memphis, TN
Is People's Custom Rx and Clinical Care, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does People's Custom Rx and Clinical Care, LLC hold a Tennessee pharmacy license?
State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions.
Has People's Custom Rx and Clinical Care, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Mar 10, 2022) and 2 FMD-145 letters (May 20, 2020 and Mar 10, 2022) for People's Custom Rx and Clinical Care, LLC. State board actions: no Tennessee Board of Pharmacy action under this exact name and city was found in the Board of Pharmacy sections of the Tennessee Department of Health’s monthly Disciplinary Action Reports (actions dated January 2004 to April 2026) on Nov 15, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- People's Custom Rx and Clinical Care, LLC
- Location
- Memphis, TN
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Mar 10, 2022
- FDA Data Dashboard inspections
- 4 inspections: 2 OAI, 2 VAI; 4 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 12 observations
- State board records
- Not checked (license records); board actions matched: 0
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as People's Custom Rx and Clinical Care, LLC, a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Mar 10, 2022 | State referral letter | State Referral Letter Issued 3/10/2022 | Not linked by FDA |
| Mar 10, 2022 | FMD-145 letter | FMD-145 Letter Issued 03/10/2022 | Not linked by FDA |
| Aug 5, 2021 | Form 483 | 483 Issued 08/05/2021 | FDA copy (archived) |
| May 20, 2020 | FMD-145 letter | FMD-145 Letter Issued 05/20/2020 | FDA copy (archived) |
| Jul 24, 2019 | Form 483 | 483 Issued 07/24/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists People's Custom Rx and Clinical Care, LLC, Memphis, TN (FEI number 3003780900), matched to this page by exact name, city and state. It lists 4 inspections: 2 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 5, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3003780900 | 1149631 |
| Jul 24, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3003780900 | 1099032 |
| Jul 2, 2018 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3003780900 | 1058512 |
| Jul 29, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3003780900 | 937640 |
Form 483s FDA has published for this site
- Aug 5, 2021: Form 483 to People's Custom Rx and Clinical Care, LLC, published Oct 5, 2021. fda.gov
- Jul 24, 2019: Form 483 to People's Custom Rx and Clinical Care, LLC, published Oct 1, 2019. fda.gov
- Jul 20, 2018: Form 483 to People's Custom Rx and Clinical Care, LLC, published Jan 17, 2024. fda.gov
- Oct 6, 2015: Form 483 to People's Custom Rx and Clinical Care, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Jul 29, 2015 to Aug 5, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 13, 2021 to Aug 5, 2021: 3 observations
- Firm on the cover
- People's Custom Rx and Clinical Care, LLC, 785 East Brookhaven Circle, Memphis, TN 38117-4501
- FEI number
- 3003780900
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- Pharma Division II 404 BNA Drive, Building 200, Suite 500 Nashville, TN 37217
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.
Specifically, the firm compounds sterile drug products which involves several aseptic manipulation steps. The firm's sterile drug product batch size can range up to <Redacted B4> for the sterile drug product Cyclosporine 1 %. The current media fills are performed only with <Redacted B4>.
Observation 2
Pressure differentials between areas with different air classifications were not monitored prior or during sterile drug production.
Specifically, there is no verification of the pressure differentials before or during sterile drug production. Pressure differentials are measured with <Redacted B4> which are not visible from within the cleanroom. The firm has no alarm system that would signal if room pressures were out of specification. Pressure differential values are only recorded <Redacted B4>.
Observation 3
Non-microbial contamination was observed in your non-sterile drug production area.
Specifically, on 07/13/2021, we observed what appeared to be drug product residue on two ceiling light fixtures in the firm's non-sterile compounding area. These light fixtures were directly above the firm's non-sterile benchtop drug product staging areas. The firm was continuously processing non-sterile drug products in this area during this inspection. On 07/16/2021, we observed that this residue was still on the light fixtures.
Inspection Jul 20, 2015 to Jul 29, 2015: 9 observations
- Firm on the cover
- , 785 Brookhaven Circle East People' s Custom Rx and Clinical Care, LLC, Memphis, TN
- FEI number
- 3003780900
- Establishment type on the cover
- 38117-4501 Producer of Sterile Drug Products
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifical ly,
1) Per your firm's SOP No. 3.300.302 "Garbing and Gloving Procedure for Sterile Compounding", when leaving the clean room technicians should replace hair covers, face masks, and gloves before re-entering the clean room. On 07/21/2015 we observed a technician leave the clean room to retrieve supplies from the ante room. This technician did not change their hair net, mask, or gloves before re-entering the clean room to perform aseptic processing.
2) Your firm does not use sterile alcohol to sanitize the technician's gloves or hood surface during aseptic processing. Your firm uses non-sterile 99% Isopropyl Alcohol.
3) The gowning components your firm uses during aseptic processing are not sterile. The hair covers, face masks, and shoe covers are stored in open containers in the ante room. Per your firm's SOP No. 3.300.302 "Garbing and Gloving Procedure for Sterile Compounding", non-sterile gowning can be reused and is to be left hanging in the ante room when not in use. ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
1) Your firm performs weekly air and surface monitoring in the prep room, ante room, and ISO 5 hoods. This is inadequate as environmental conditions are not monitored every day production occurs.
2) Your procedure for weekly air and surface monitoring is inadequate as you only take 1 surface sample and 1 air sample from each room. Your clean room contains 2 hoods; therefore, each hood is not being monitored when you do perform air and surface sampling.
3) Your compounding technicians’ fingertips are monitored every 6 months. Per your firm’s SOP 3.300.604 "Environmental Monitoring of the Aseptic Compounding Area: Gloved Fingertip Testing", your aseptic technicians' fingertips should be monitored biweekly. Neither is adequate as technicians are not monitored each time they perform aseptic processes.
Observation 3
The flow of components, drug product containers, closures, in-process materials, and drug products though the building is not designed to prevent contamination.
Specifically;
1) Per your firm's SOP 3.300.308 "General Aseptic Compounding Procedures when Working within the Secondary Engineering Controls and Primary Engineering Controls", all supplies should be decontaminated in the ante room and transferred into a clean sanitized cart for introduction into the clean room. On 07/2112015 we observed a technician carry 3 plastic totes containing components (sterile syringes, sterile needles, compounded stock solution) to be used during aseptic processing into the ante room. After gowning, the technician stacked these totes and entered the clean room without decontaminating the totes or components. The technician was processing Myers vitamin injections with Vitamin C.
2) Per your firm's SOP 3.300.308 "General Aseptic Compounding Procedures when Working within the Secondary
Engineering Controls and Primary Engineering Controls", decontamination should be performed as supplies are introduced into the aseptic work area. ...
Observation 4
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Specifically,
1) Your Cleanroom Certification Report dated 03/27/2015 indicates smoke studies were performed for the ISO 5 hoods; however, these studies were not video recorded or documented. Also these studies were not performed in dynamic conditions.
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
Specifically,
1) Your firm produces stock solutions used to fill individual prescriptions. Your stock solution lot sizes supply the firm with enough product to fill approximately 3 weeks of prescriptions. Each stock solution container can be used for multiple fills. You have not conducted the appropriate tests to validate this process.
2) Your firm has not validated your sterilization process for autoclaving rubber stoppers and finished drug products (suspensions including prednisolone and stanozolol).
3) Your firm has not validated the process of depyrogenating/sterilizing glassware via a dry heat oven. The glassware is used in the mixing and holding of drug products to be aseptically filled or terminally sterilized.
4) Your firm has not validated the process of terminal sterilization for oil based drug products using a dry heat oven.
Observation 6
Routine calibration of equipment is not performed according to a written program designed to assure proper performance .
Specifically,
1) Your firm uses a Boekel model incubator for sterility samples. The directions for use for the TSB syringes your firm uses state to incubate at 22.5°C +/-2 .5°C. During a review of your firm's temperature logs for this incubator for the last 4 months (April-July 2015), it was found that temperature was out of range for this entire time period. The temperature ranged from 25.2°C to 30.8°C.
2) Your firm uses a Lab-Line model incubator for environmental monitoring. The directions for use for the TSA plates your firm uses state to incubate at 35°C +/- 2°C. During a review of your firm's temperature logs for this incubator for the last 4 months (April-July 2015), it was found that temperature was out of range for 37 days (approximately 30% of the time) during this time period. The temperature range was 39°C to 44°C for the out of range readings.
Observation 7
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Specifically, .
Your firm uses sterile isopropyl alcohol, Sporicidin, and Accel TB disinfectant for daily cleaning of the ISO 5 hoods and clean room. Per your firm's SOP 3.300.303 "Disinfectant Selection and Use Rotation", these 3 cleaners are rotated on a quarterly cycle with sterile isopropyl alcohol being used twice. This only allows for a sporacide to be used for 1 quarter of the year for cleaning your ISO 5 hoods and clean room.
Observation 8
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically,
Your firm does not conduct identity and potency testing of each lot of drug produced.
Observation 9
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
Your firm has not performed stability studies for your sterile products that include ID, potency, degradant, impurity, and other stability indicating parameters. Beyond use dates of greater than 48 hours are given to sterile injectable drugs that do not contain preservatives.
Linked 483s whose text is not shown
- Jul 24, 2019: FDA document 131179: its numbered observations could not be read reliably from the PDF text.
- Jul 20, 2018: FDA document 114343: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. Board actions source.
What this covers: Board of Pharmacy actions against pharmacies and other business licensees from the Department of Health’s monthly Disciplinary Action Reports (260 of 263 monthly reports read, 137 with a Board of Pharmacy section). The reports list final board actions for the month named, worded as the department gives them; each action is dated by its report month. Actions against individual pharmacists and technicians are not copied. An entry that gives a city but no state is read as a Tennessee address, as the reports write them. Tennessee pharmacy licenses are not checked. Actions in the data are dated January 2004 to April 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Tennessee Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.